Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103407 | 0.88 | HCAR3 (0.64) | HCAR3KAT2BMAPTALDH1A1TDP1 | |
| SCHEMBL1886423 | 0.84 | ALDH1A1 (0.62) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL9458424 | 0.84 | HCAR3 (0.58) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL9663414 | 0.82 | ALDH1A1 (0.59) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL28448306 | 0.82 | HCAR3 (0.56) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL18327527 | 0.82 | HCAR3 (0.56) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL18075096 | 0.81 | ALDH1A1 (0.67) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL18075204 | 0.81 | HCAR3 (0.67) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL10582049 | 0.81 | LMNA (0.70) | HCAR3LMNAKAT2BMAPTALDH1A1 | |
| SCHEMBL10891363 | 0.81 | HCAR3 (0.66) | HCAR3LMNAKAT2BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217416-A | Preparation method of benzimidazole drug intermediate 3-nitro-4-ethylamino benzyl alcohol | 黄淮学院 | 2023-06-06 | — | — | CN | claimed |
| CN-116217416-A | Preparation method of benzimidazole drug intermediate 3-nitro-4-ethylamino benzyl alcohol | 黄淮学院 | 2023-06-06 | — | — | CN | disclosed |
| CN-116217416-A | Preparation method of benzimidazole drug intermediate 3-nitro-4-ethylamino benzyl alcohol | 黄淮学院 | 2023-06-06 | — | — | CN | disclosed |
| CN-116217416-A | Preparation method of benzimidazole drug intermediate 3-nitro-4-ethylamino benzyl alcohol | 黄淮学院 | 2023-06-06 | — | — | CN | disclosed |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-107635989-B | Benzimidazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权开发有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| EP-1442028-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6673815-B2 | MODULATE BLOOD GLUCOSE LEVELS, TRIGLYCERIDE LEVELS, INSULIN LEVELS AND NON-ESTERIFIED FATTY ACID LEVELS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-06 | — | — | US | disclosed |
| US-20030130306-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2003040114-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | HCAR3 982/4885LMNA 4374/4885KAT2B 25/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | HCAR3 982/4885LMNA 4374/4885KAT2B 25/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | HCAR3 982/4885LMNA 4374/4885KAT2B 25/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | HCAR3 982/4885LMNA 4374/4885KAT2B 25/4885 |
| US-20030130306-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, GCGR | HCAR3 449/4885LMNA 547/4885KAT2B 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.